David Kreutter is an executive with 30 years of experience in the pharmaceutical industry at Pfizer. His roles have included R&D, decision analysis and strategic portfolio management, commercial operations and global business analytics. He has a proven track record in forming and leading high-performing teams, and leading large-scale innovation in strategy, analytics and operations.
Kreutter led the Portfolio and Decision Analysis Group, which was awarded the Raiffa-Howard Award in 2016 for Organizational Decision Quality. Under the sponsorship of the CEO and the Scientific Advisory Committee of the Board of Directors, he led the development of a global therapeutic area strategy that aligned the R&D, Medical, and Commercial divisions on the areas of focus for internal pursuit and for licensing activities. He led the prioritization of the development portfolio that was also used as the framework for in-licensing decisions.
Kreutter led a large US commercial model innovation focused on enhancing customer centricity through digital and analytics technologies. He also led the formation of a mixed insourced/outsourced global analytics operating model with an advanced analytics COE and regional delivery hubs. Recently he led a broad industry/academia collaboration with IBM, Partners Healthcare and the Broad Institute focused on using EMR and big data to understand disease risk and progression to enable a vision of precision medicine.
Kreutter is currently leveraging his expertise and experience by providing strategy consulting services to the life sciences industry, and advisory services to life sciences start-up companies. He is an executive advisor to PwC and to IQVIA, focusing on organizational transformation and digital strategies. He is on the bioinformatics advisory board for NYU Tandon School of Engineering, is an advisor to Rxvantage, and is a director for nQ Medical.